Fact based stock research
Laboratorios Farmaceuticos Rovi (BME:ROVI)

ES0157261019

Laboratorios Farmaceuticos Rovi stock research in summary

rovi.es


Laboratorios Farmaceuticos Rovi shares are more expensive than other comparable stocks. They show above average growth and are safely financed, but are poor value. We recommend evaluating whether the future of the company Laboratorios Farmaceuticos Rovi is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.


Latest Obermatt Ranks


Country Spain
Industry Pharmaceuticals
Index
Size class Medium

October 7, 2021. Stock data may be delayed. Login to get the most recent research.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Laboratorios Farmaceuticos Rovi from October 7, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.